RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in the management of cancer. The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps oncologists to rapidly assess the effectiveness of cancer chemotherapy. The RDA™ test can determine whether chemotherapy is working effectively in an individual patient early in treatment, thereby enabling more effective clinical decision-making. RDA™ utilizes a needle biopsy taken during cancer treatment to determine the degree of ribosomal RNA (rRNA) disruption,…
Author: Brett Johnson
“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection. 20/20 GeneSystems is pioneering a novel approach to cancer detection, called “20/20 Hindsight”, that uses continuous machine learning to utilize large patient data sets of biomarker values to evaluate clinical factors such as age, gender, and smoking history for early cancer detection. 20/20 GeneSystems’ “20/20 Hindsight” platform can aid in the early detection of cancer by improving the accuracy of the most widely used cancer biomarkers. 20/20 GeneSystems was founded in…
Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system. QuantumCyte’s single-cell analysis system, known as Q1©, can predict drug efficacy in a way that is rapid, non-invasive, and accurate. Q1© is the first high-throughput single-cell analysis platform to correlate gene expression with phenotypic data. The Q1© platform leverages QuantumCyte’s ArraySeQ© chemistry and a novel reagent exchange system to enable high-efficiency transcriptome capture, low running costs, and new applications in systems biology, drug discovery, and predictive medicine. QuantumCyte’s high-density dome array…
CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy. The therapy genetically edits patients’ T cells to express a CAR specific to the type of cancer present, which enables targeted killing of cancer cells. The U.S. Food & Drug Administration has awarded Aurora Biopharma’s CAR T Cell Therapy with its Breakthrough Therapy Designation for the therapy’s treatment of pediatric and adult acute lymphoblastic leukemia…